Pure Global
NCT06237062

Migraine Survey in Gulf Region

Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study
Novartis Pharmaceuticals·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Migraine
Drug/Device/Intervention
erenumab
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Novartis Pharmaceuticals
Funder
Novartis
Timeline & enrollment
Phase
N/A
Start date
Apr 30, 2024
End date
Jan 30, 2025
Enrollment
200 participants
Primary outcome

Mean score in the Treatment Satisfaction Questionnaire for Erenumab (TSQM) overall satisfaction scale score version 1.4

Summary

The objective of this study is to evaluate the effect of erenumab on medication-specific
 treatment satisfaction in patients newly started on erenumab over 12 weeks

ICD-10 classifications
MigraineOther migraineMigraine, unspecifiedComplicated migraineHeadache
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06237062
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06237062 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Not yet recruiting. The study focuses on Migraine. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.